What is the dose of IV aspirin in acute coronary syndrome, and what literature supports this? What is the bioavailability of enteral and PR aspirin?

No direct evidence for the bioavailability of enteral or PR aspirin in acute coronary syndrome patients was identified. For IV aspirin dosing, 250 mg and 500 mg have been used effectively to inhibit platelet function in such settings.